Merkel cell carcinoma in Latin America: a contribution from an expanded access program for avelumab to address issues from experts' recommendations.

Autor: Munhoz RR; Sarcoma and Melanoma Group, Oncology Center and Coordinator of the Medical Oncology Fellowship Program, Instituto do Cancer do Estado de São Paulo, Hospital Sirio Libanes, São Paulo, Brazil., Cayol F; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Corrales L; Hospital Clínica Bíblica, CIMCA (Centro de Investigación y Manejo del Cáncer), San José, Costa Rica., Gerson R; Centro de Cáncer Hospital ABC, Mexico City, Mexico., Tilli M; An affiliate of Merck KGaA, Merck SA, Tronador 4890, Buenos Aires, Argentina. malena.tilli@merckgroup.com., Barreto EO; Centro Oncológico del Norte, Antofagasta, Chile., Sánchez Castillo JO; Hospital San Ignacio, Bogotá, Colombia., Schmerling RA; Hospital São José, São José, Brazil., Cinat G; Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 Apr; Vol. 70 (4), pp. 1031-1036. Date of Electronic Publication: 2020 Oct 26.